ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
|
|
- Leslie Parsons
- 5 years ago
- Views:
Transcription
1 ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France)
2 DEFINITION A metabolic disorder characterized by chronic hyper glycaemia resulting from defects in insulin secretion or action or both. Fasting plasma glucose 7 mmol/l. HbA1C 6.5%. On two consecutive measures. 2 hour post load plasma glucose 11.1 mmol/l.
3 Cardiovascular risk assessment DM = high cardiovascular risk. DM + one other risk factor / organ damage = very high risk. ESC Guidelines, CV Prevention, 2012
4 Risk Assessment Classical risk factors (smoking, BP, lipids, lifestyle, family history). Glycaemic status. Macro vascular disease (coronary / cerebrovascular / HF / PAD). Micro vascular disease (retinopathy / nephropathy / neuropathy). Arrhythmias.
5 Multifactorial management of CV risk Patient education and empowerment. Life style advice. Smoking cessation. Personalised treatment of blood pressure, lipids, glycemic control and thrombotic risk.
6 Steno-2 Gaede P et al., N Engl J Med, 2008;358:580-91
7 Cardiovascular safety of glucose lowering agents METFORMIN? + SULPHONYLUREA? INSULIN? + (ORIGIN) PIOGLITAZONE GLINIDES = GLP1 AGONISTS DPP4 Inhibitors Na Glucose Co Transporter 2 (SGLT-2) inhibitors + (PRO ACTIVE) - HF + (ELIXA) + (SAVOR EXAMINE-TECOS) HF - SAVOR HF +TECOS?( + EMPAREG)
8 Proportion with event Proportion with event UKPDS 80: The Legacy Effect of Intensive Glucose Control Myocardial Infarction Myocardial Infarction Conventional (n = 1138) Sulfonylurea/Insulin (n = 2729) 15% reduction P = Years since randomization Conventional Therapy Sulfonylurea-Insulin Conventional (n = 411) Metformin (n = 342) 33% reduction P = Years since randomization Conventional Therapy Metformin In 10-yr post-trial follow-up, between-group A1c differences lost after 1 yr. Intensive treatment with sulfonylurea and/or insulin also resulted in a persistent 24% reduction in microvascular disease (P = 0.001) Holman, RR. et al. N Engl J Med. 2008;359:1577.
9 N Engl J Med, 2012 Jul 26;367(4): O R I G I N
10 CV Death, MI or Ischemic CVA (%) Primary Endpoint HR % CI p<0.001 (non-inferiority) p=0.99 (superiority) 2y KM Saxagliptin 7.3% Placebo 7.2% Months Placebo Saxagliptin
11 EXAMINE White WB, N Engl J Med, September 2, DOI: /NEJMOA
12 Percent of patients with an event PRIMARY COMPOSITE CARDIOVASCULAR OUTCOME* PER PROTOCOL ANALYSIS FOR NONINFERIORITY Placebo Sitagliptin HR (95% CI): 0.98 (0.88, 1.09) Noninferiority P< Patients at risk: Months in the trial Sitaglipin 7,257 6,857 6,519 6,275 5,931 5,616 3,919 2,896 1,748 1,028 Placebo 7,266 6,846 6,449 6,165 5,803 5,421 3,780 2,743 1,690 1,005 Median FU 2 years F. Van de Werf (Leuven, BE), FP 4128 * CV death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina
13 Meta-analysis of Intensive Control of Glucose (n= patients) -5 Trials UKPDS / PROactive / ADVANCE / VADT / ACCORD Non fatal MI HbA 1 C = 0.9% Death HbA 1 C = 0.9% Ray KK et al, Lancet 2009;373:
14 Effects of more VS less intensive glycaemic control Number of events Trials All-cause mortality ACCORD ADVANCE UKPDS VADT Overall Cardiovascular death ACCORD ADVANCE UKPDS VADT Overall (annual event rate, %) more less intensive 257 (1.41 ) 203 ( 1.14 ) 498 ( 1.86 ) 533 ( 1.99 ) 123 ( 0.13 ) 53 ( 0.25 ) 102 ( 2.22 ) 95 ( 2.06 ) (0.79 ) 94 ( 0.56 ) 253 ( 0.95 ) 289 ( 1.08 ) 71 ( 0.53 ) 29 ( 0.52 ) 38 ( 0.83 ) 29 ( 0.63 ) intensive HbA1c (%) Favors more intensive Favors less intensive Hazard ratio (95% CI) 1.22 ( ) 0.93 ( ) 0.96 ( ) 1.07 ( ) 1.04 ( ) (Q=5.71, p =0.13, I 2 =47.5%) 1.35 ( ) 0.88 ( ) 1.02 ( ) 1.32 ( ) 1.10 ( ) (Q=8.61, p =0.04, I 2 =65.1%) Non-cardiovascular death ACCORD ADVANCE UKPDS VADT Overall 115 (0.63 ) 98 ( 0.55 ) 245 ( 0.92 ) 244 ( 0.91 ) 52 ( 0.39 ) 24 ( 0.43 ) 64 (1.40 ) 66 ( 1.43 ) ( ) 1.00 ( ) 0.90 ( ) 0.97 ( ) 1.02 ( ) (Q=0.99, p =0.80, I 2 =0.0%) Hazard ratio (95% CI) Turnbull et al Diabetologia August 09 (CONTROL collaboration)
15 Intensive Glucose Control Microvascular disease Macrovascular Medium Term Macrovascular Long Term (DCCT UKPDS) (ACCORD, ADVANCE, VADT, ORIGIN) except recent DM w/o CVD (DCCT UKPDS) Individualized Care
16 Glycaemic control individualised care HbA1c <53 mmol/mol (7.0%) HbA1c mmol/mol ( %) in selected patients with short disease duration long life expectancy no significant cardiovascular disease HbA1c <58 64 mmol/mol ( %) in elderly patients with long-standing and/or complicated disease All targets to be achieved without hypoglycaemia or other adverse effects
17 Heart Failure T2 DM is a major risk factor for HF. Combination of T2 DM and HF increases substantially the risk of mortality. Pharmacological management similar to non DM. Some antidiabetic drugs contra indicated (glitazones).
18 Individual Endpoints ITT Population 2-year KM rate (%) Placebo (N=8,212) Saxagliptin (N=8,280) HR p value for superiority CV Death ( ) 0.72 MI ( ) 0.52 Ischemic Stroke ( ) 0.38 Hosp for Cor. Revasc ( ) 0.18 Hosp for UA ( ) 0.24 Hosp for Heart Failure ( ) All-Cause Mortality ( ) 0.15
19 Percent of patients with an event TIME TO FIRST HOSPITALIZATION FOR HEART FAILURE* Placebo Sitagliptin HR (95% CI): 1.00 ( ) P = 0.95 Patients at risk: Months in the trial Sitaglipin 7,332 7,189 7,036 6,917 6,780 6,619 4,728 3,515 2,175 1,324 Placebo 7,339 7,204 7,025 6,903 6,712 6,549 4,599 3,443 2,131 1,315 F. Van de Werf (Leuven, BE), FP 4128 * ITT population
20 Blood pressure control in diabetes Recommendations Class a Level b Blood pressure control is recommended in patients with DM and hypertension to lower the risk of cardiovascular events. It is recommended that a patient with hypertension and DM is treated in an individualized manner, targeting a blood pressure of < 140/85 mmhg. It is recommended that a combination of blood pressure lowering agents is used to archiveve blood pressure control. A RAAS blocker (ACE-I or ARB) is recommended in the treatment of hypertension in DM, particularly in the presence of proteinuria or microalbuminuria. Simultaneous administration of two RAAS blockers should be avoided in patients with DM. I I I I III A A A A B
21 Blood Pressure Meta-analysis 13 RCTs Intensive BP 135 Standard BP 140 All cause mortality HR = 0.90 Stroke HR = 0.83 Serious adverse events HR = 1.40 Bangalore, Circulation, 2011;123, 2795
22 Blood pressure control treatment targets - individualised care Lowering systolic blood pressure 140/ 85 mm Hg has favourable cardiovascular effects. A systolic blood pressure target <130 mm Hg may be considered in the presence of nephropathy with overt proteinuria. A blood pressure <130/80 mm Hg may increase the risk for adverse events in elderly patients and those with a long diabetes duration. The risk/benefit balance of intensive blood pressure management needs to be carefully considered and individualised.
23 Recommendations for lipid control in patients with diabetes Recommendations Class Level Statin therapy is recommended in patients with T1DM and T2DM at very high risk (i.e. if combined with documented CVD, severe CKD or with one or more CV risk factors and/or target organ damage) with an LDL-C target of <1.8 mmol/l (<70 mg/dl) or at least a 50% LDL-C reduction if this target goal cannot be reached. Statin therapy is recommended in patients with T2DM at high risk (without any other CV risk factor and free of target organ damage) with an LDL-C target of <2.5 mmol/l (<100 mg/dl). Statins may be considered in T1DM patients at high risk for cardiovascular events irrespective of the basal LDL-C concentration. It may be considered to have a secondary goal of non HDL-C <2.6 mmol/l (<100 mg/dl) in patients with DM at very high risk and of <3.3 mmol/l (<130 mg/dl) in patients at high risk. Intensification of statin therapy should be considered before the introduction of combination therapy with the addition of ezetimibe. The use of drugs that increase HDL-C to prevent CVD in T2DM is not recommended. I I IIb IIb IIa III A A C C C A
24 Options for Revascularisation 1. Acute coronary syndromes: Early revascularization (as in non DM). 2. Stable coronary artery disease : CABG preferred option if myocardial area at risk is large. PCI with DES may be performed for symptom control in single and two-vessel disease.
25 Event free survival (%) Myocardial revascularisation vs. medical therapy in people with diabetes Event free survival in the BARI 2 D study Revascularisation 77% 60 Medical therapy 76% 40 58% of medical patients did not need revascularisation during follow-up Follow-up (years) BARI 2D Study group New Engl J Med 2009; 360: 2503
26 Event free survival (%) Myocardial revascularisation vs. medical therapy in people with diabetes 100 Event free survival in the BARI 2 D study CABG stratum 80 Revascularisation 78% Medical therapy 70% 60 p = Compared to medical treatment alone prompt revascularisation decreased major CV events in the CABG stratum Follow up (years) BARI 2D Study group New Engl J Med 2009; 360: 2503
27 CABG vs PCI Clinical Evidence Meta-analysis PCI diabetes (bare metal stents) CABG diabetes CABG no diabetes PCI no diabetes (BMS) patients with Diabetes Hlatky et al Lancet 2009: 1190
28 Death, myocardial infarction, or stroke (%) Death from any cause (%) CABG vs. PCI in people with diabetes The FREEDOM trial Primary Outcome Death p=0.005 by log rank test 5-year event rate 26.6 vs.18.7% p=0.049 by log rank test 5-year event rate 16.3 vs.10.9% PCI CABG Years since randomization 7.9% PCI CABG Years since randomization 5.4% Farkouh et al New Engl J Med 2012; 367: 2375
29 Revascularisation in people with diabetes Recommendations Class Level Optimal medical treatment should be considered as preferred treatment in patients with stable CAD and DM unless there are large areas of ischaemia or significant left main or proximal LAD lesion. CABG is recommended in patients with DM and multivessel or complex (SYNTAX Score >22) CAD to improve survival free from major cardiovascular events. PCI for symptom control may be considered as an alternative to CABG in patients with DM and less complex multivessel CAD (SYNTAX score 22) in need of revascularization. Primary PCI is recommended over fibrinolysis in DM patients presenting with STEMI if performed within recommended time limits. In DM patients subjected to PCI, DES rather than BMS are recommended to reduce risk of target vessel revascularization. Renal function should be carefully monitored after coronary angiography/pci in all patients on metformin. If renal function deteriorates in patients on metformin undergoing coronary angiography/pci it is recommended to withhold treatment for 48 h or until renal function has returned to its initial level. IIa I IIb I I I I B A B B A C C
30 Recommendation for antiplatelet therapy in people with diabetes Recommendations Class Level Antiplatelet therapy with aspirin in DM-patients at low CVD risk is not recommended. Antiplatelet therapy for primary prevention may be considered in high risk patients with DM on an individual basis. Aspirin at a dose of mg/day is recommended as secondary prevention in DM. III IIb I A C A A P2Y 12 receptor blocker is recommended in patients with DM and ACS for 1 year and in those subjected to PCI (duration depending on stent type). In patients with PCI for ACS preferably prasugrel or ticagrelor should be given. I A Clopidogrel is recommended as an alternative antiplatelet therapy in case of aspirin intolerance. I B
31 2013 ESC GUIDELINES LAUNCHED!
32
Diabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationMaster Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Coronary interventions in patients with diabetes Lars Rydén Karolinska Institutet Stockholm, Sweden
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More information2013 ESC Guidelines on Diabetes, Pre-diabetes and Cardiovascular Diseases Developed in Collaboration with EASD
2013 ES Guidelines on Diabetes, Pre-diabetes and ardiovascular Diseases Developed in ollaboration with ESD Paul Valensi Department of Endocrinology Diabetology Nutrition Jean Verdier Hospital Paris-Nord
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationEuropean Heart Journal 2015 doi: /eurheartj/ehv320
European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 1 2 Clinical implications of high-sensivity troponin assays European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 Conditions other than Type
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ
ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ Νίκος Μεζίλης MD, FESC Κλινική Άγιος Λουκάς Why diabetes is associated with restenosis endothelial dysfunction metabolic alterations accelerated platelet deposition
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationCardiovascular risk reduction in diabetes Lipids (NICE CG181)
Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Primary Prevention T1DM Offer Atorvastatin 20mg if >40 years old Diabetes duration >10 years Established nephropathy Other CVS risk factors
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationStephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital
Stephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital Financial Disclosures Consulting Panel for GSK on Hepatitis Vaccines Case Study BH is a 67 y/o female with T2 DM for
More informationHeart Failure Management in T2 DM A Practical Approach. David Fitchett MD St Michael s Hospital Toronto
Heart Failure Management in T2 DM A Practical Approach David Fitchett MD St Michael s Hospital Toronto Faculty: Faculty Disclosure David Fitchett MD,, FRCP(C) Associate Professor of Medicine, University
More informationPREVENTION. Pr Michel KOMAJDA ESC CONGRESS HIGHLIGHTS
ESC CONGRESS HIGHLIGHTS PREVENTION Pr Michel KOMAJDA Dept of Cardiology University Pierre & Marie Curie Pitie Salpétrière Hospital PARIS France Thank you to B Williams and S Sharma michel.komajda@aphp.fr
More informationUpdate on Diabetes. Ketan Dhatariya. Why it s Not Just About Glucose Lowering Any More. Consultant in Diabetes NNUH
Update on Diabetes Why it s Not Just About Glucose Lowering Any More Ketan Dhatariya Consultant in Diabetes NNUH The Story So Far.. DCCT Retinopathy Neuropathy Nephropathy Intensive glucose control in
More informationCardiovascular Consequences of Diabetes Mellitus
Cardiovascular Consequences of Diabetes Mellitus William J. Elliott, M.D., Ph.D. 05 MAY 18 Disclosure Statement The speaker s research and educational activities have been supported in the past (but NOT
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationDIABETES AND METABOLIC SYNDROME
TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 48,508 20,091 41.4% 61.1 4.3 4/7 (57.1%) HR PROactive (Dormandy et al 61
More informationManagement of cardiovascular disease - coronary interventions -
Master Classes in Preventive Cardiology I Management of diabetes in patients with CVD European Heart House Management of cardiovascular disease - coronary interventions - Francesco Cosentino MD, PhD, FESC
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationPrevention of MACROvascular Complications of Diabetes
Prevention of MACROvascular Complications of Diabetes Matt Bouchonville, MD, CDE Endocrinology Division University of New Mexico School of Medicine July 12, 2018 Conflicts of Interest None Objectives 1.
More informationTreating the elderly patients with type 2 diabetes mellitus
Treating the elderly patients with type 2 diabetes mellitus Niki Katsiki MSc, PhD, MD, FRSPH IASO/EASO Scope Member EASD Diabetes & Cardiovascular Disease Group Member Member of the Executive Board of
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More information2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco
Modern Management of Patients with Stable Coronary Artery Disease Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Scope of the Problem Prevalence of CAD: 17.6 million
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationAn Update on Guidelines and Evidence of the Treatment of Type 2 Diabetes Mellitus
Nevada Academy of Family Physicians 29 th Annual Summer CME Meeting August 3 5, 2018 An Update on Guidelines and Evidence of the Treatment of Type 2 Diabetes Mellitus Presented by: James D. Honeycutt,
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationSulfoniluree e glinidi: pro e contro
Sulfoniluree e glinidi: pro e contro Giorgio Sesti Università Magna Graecia di Catanzaro ITALY T2DM anti-hyperglycaemic therapy: general recommendations Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596,
More informationReview. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction
Review Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Diabetes mellitus is increasingly recognized as an essentially vascular
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationCARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE
CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE *Peter M. Nilsson Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden *Correspondence
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More information